Targeting tyrosine kinases: A novel therapeutic strategy for systemic sclerosis Review uri icon

Overview

MeSH Major

  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases
  • Scleroderma, Systemic

abstract

  • Tyrosine kinase inhibition as a potential strategy for the treatment of systemic sclerosis has been gaining more widespread interest based on preclinical data and open-label experiences. Large, multicenter, double-blind, randomized controlled trials are needed to assess the efficacy and safety of this approach in this complex disease.

publication date

  • November 2010

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1097/BOR.0b013e32833f1105

PubMed ID

  • 20827202

Additional Document Info

start page

  • 690

end page

  • 5

volume

  • 22

number

  • 6